Current Projects.

We've worked with numerous clients in the past to help them find and interview stakeholders across multiple verticals to get answers to their important business questions.

The $21 Billion Bet: What Abbott-Exact Sciences Means for the Future of Liquid Biopsy

The $21 Billion Bet: What Abbott-Exact Sciences Means for the Future of Liquid Biopsy

Abbott's $21B Exact Sciences acquisition caps a quarter of mega-deals, FDA filings, and legislation that signals liquid biopsy's shift from innovation to infrastructure.
Oops! Something went wrong while submitting the form.

Current Projects.

We've worked with numerous clients in the past to help them find and interview stakeholders across multiple verticals to get answers to their important business questions.